科兴生物制药股份有限公司 目 录 第一章 总 则 第一条 为规范科兴生物制药股份有限公司（以下简称"公司"）的关联交易， 保证公司关联交易的公允性，维护公司及公司全体股东的合法权益，根据《中华 人民共和国公司法》（以下称"《公司法》"）《企业会计准则第 36 号——关联方 披露》《上海证券交易所科创板股票上市规则》（以下简称"《科创板股票上市规 科兴生物制药股份有限公司 （修订稿） 二〇二五年七月 《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》等 则》"） 有关法律法规及《科兴生物制药股份有限公司章程》（以下称"《公司章程》"） 的有关规定，结合公司实际情况，制订本制度。 第二条 本制度对公司股东、董事和高级管理人员具有约束力，公司股东、 董事和高级管理人员必须遵守。 第三条 公司关联交易应当定价公允、决策程序合规、信息披露规范，保证 关联交易的合法性、必要性、合理性和公允性，保持公司的独立性，不得利用关 联交易调节财务指标，损害公司利益。 第四条 关联交易活动应遵循以下基本原则： （一）平等、自愿、等价、有偿的原则； （二）公平、公正、公开的原则； （三）不损害公司及非关联股东合法权益的 ...

有关规定，结合公司实际情况，制定本细则。 科兴生物制药股份有限公司 二〇二五年七月 科兴生物制药股份有限公司 第一章 总 则 第一条 为规范科兴生物制药股份有限公司（以下简称"公司"或"本公司"） 总经理、副总经理及其他高级管理人员的管理水平和管理效率，进一步规范公司 总经理、副总经理及其他高级管理人员的议事方式和决策程序，保证总经理、副 总经理及其他高级管理人员能够合法有效地履行其职责，根据《中华人民共和国 公司法》、《中华人民共和国证券法》、《上市公司治理准则》、《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、法规、规 范性文件以及《科兴生物制药股份有限公司章程》 （以下简称"《公司章程》"）的 第二条 本细则所称高级管理人员是指公司的总经理、副总经理、财务总监、 董事会秘书和《公司章程》规定的其他人员。 第三条 公司依法设置总经理一名，总经理由董事长提名，并由董事会批准 后聘任或解聘。总经理主持公司日常经营活动和管理工作组织，负责组织实施董 事会决议，对董事会负责。 公司设置其他高级管理人员若干名，协助总经理工作。其他高级管理人员是 指公司的副总经理、董事会秘书、财务总监 ...

Core Points - The document outlines the information disclosure management system of Sinovac Biotech Ltd, ensuring timely, accurate, and complete disclosure of significant information that may impact the trading price of the company's securities and investor decisions [2][3][4]. Group 1: General Principles - The information disclosure is a continuous responsibility of the company, requiring compliance with laws, regulations, and relevant rules [6][7]. - Information must be disclosed truthfully, accurately, and completely, avoiding misleading statements or omissions [7][8]. - All investors should receive disclosed information simultaneously, with no advance disclosure to any individual or entity [7][8]. Group 2: Disclosure Obligations - The company and its subsidiaries must adhere to the established disclosure regulations [3][4]. - Major events that could significantly affect the company's securities must be disclosed immediately [14][15]. - The company must disclose regular reports, including annual, semi-annual, and quarterly reports, within specified timeframes [21][22]. Group 3: Reporting Procedures - The internal process for handling undisclosed information begins when a significant event occurs or is anticipated [20]. - The board of directors must approve all periodic reports before disclosure [30][31]. - Any discrepancies between preliminary and final reports must be corrected promptly [12][28]. Group 4: Media and Communication - The company must use qualified media for disclosures, ensuring that information is not published in other media before it appears in the designated channels [48][49]. - The board secretary is responsible for coordinating and organizing the disclosure process, ensuring compliance with all regulations [50][51]. Group 5: Accountability and Compliance - Directors and senior management are accountable for the accuracy and completeness of disclosed information [64][65]. - Violations of disclosure obligations may result in disciplinary actions against responsible individuals [66][67]. - The company must review its disclosure practices following any regulatory penalties or criticisms [67][68].

Core Points - The document outlines the insider information management system of Sinovac Biotech Ltd, aiming to ensure fair information disclosure and prevent insider trading [1][2][3] - The board of directors is responsible for managing insider information and ensuring the accuracy and completeness of insider information registries [2][3] - Insider information is defined as any undisclosed information that could significantly impact the company's operations, finances, or stock prices [1][2] Insider Information and Management - Insider information includes significant changes in business strategy, major investments, important contracts, and any events that could lead to substantial financial losses [1][2] - The company must maintain a registry of individuals who have access to insider information, including their roles and the nature of the information they possess [3][4] - All parties involved in the management of insider information must ensure confidentiality and are prohibited from trading based on undisclosed information [6][7] Responsibilities and Compliance - The company is required to report insider information registries and significant event memorandums to regulatory authorities within five trading days after public disclosure [6][7] - Individuals with insider information must sign confidentiality agreements and are prohibited from disclosing or trading based on that information until it is publicly available [6][9] - Violations of the insider information management system can result in disciplinary actions, including termination and legal consequences [7][8]

Core Viewpoint - The company aims to establish a robust investor relations management system to enhance communication with investors, protect their rights, and improve corporate governance and overall value [1][3]. Group 1: Principles and Objectives of Investor Relations Management - The investor relations management should adhere to principles of compliance, equality, proactivity, honesty, efficiency, and interactive communication [2][3]. - The primary objectives include fostering a positive relationship with investors, building a stable investor base, promoting a culture of respect for investors, maximizing overall corporate benefits, and increasing transparency in information disclosure [3][4]. Group 2: Communication and Disclosure Practices - The company will communicate key information regarding its development strategy, financial status, and significant events through various channels, including regular reports, shareholder meetings, and the company website [4][6]. - The company is committed to timely and fair information disclosure, ensuring that all communications are clear, accurate, and devoid of misleading statements [8][10]. Group 3: Organizational Structure and Responsibilities - The board secretary is designated as the head of investor relations management, overseeing daily operations and ensuring compliance with relevant regulations [11][12]. - The company will maintain a database for investor relations management, documenting all activities and communications to ensure transparency and accountability [13][14].

Core Points - The company establishes a remuneration and assessment committee to enhance governance structure and manage the compensation of directors and senior management [1][2] - The committee consists of three directors, including two independent directors, and is responsible for formulating and reviewing compensation policies and assessment standards [2][3] - The committee's decisions must be submitted to the board for approval, and any non-accepted recommendations must be documented with reasons [3][4] Group 1 - The remuneration and assessment committee is tasked with developing assessment standards for directors and senior management, as well as reviewing compensation mechanisms [3][4] - The committee's decisions are subject to board approval and must be disclosed if not fully adopted [3][7] - The committee is supported by the company's human resources center, which provides necessary operational data and performance metrics [4][5] Group 2 - The committee meetings require a two-thirds attendance of members to be valid, and decisions are made by majority vote [6][7] - Meeting records must include details such as date, attendees, agenda, and voting results, and are kept as company archives [7][8] - The committee has the authority to invite other directors and senior management to meetings for reporting or questioning [6][7]

Core Points - The document outlines the rules and procedures for the board of directors of Sinovac Biotech Ltd, aiming to enhance decision-making efficiency and ensure compliance with relevant laws and regulations [1][25]. Group 1: General Provisions - The board of directors is responsible to the shareholders' meeting and exercises its powers according to the law and the company's articles of association [1]. - The board meetings are the primary form of decision-making for the directors, and attendance is essential for fulfilling their duties [1][2]. Group 2: Directors - Directors must be elected or replaced by the shareholders' meeting and serve a term of three years, with the possibility of re-election [4]. - Directors have a fiduciary duty to act in the best interests of the company and its shareholders, avoiding conflicts of interest and not misusing their authority for personal gain [9][10]. Group 3: Board of Directors - The board consists of eight directors, including three independent directors and employee representatives [9]. - The board has various powers, including convening shareholders' meetings, executing resolutions, and making decisions on significant investments and operational plans [17]. Group 4: Meeting Procedures - The board must hold at least two regular meetings annually, with provisions for calling temporary meetings under specific circumstances [13][25]. - Decisions require a majority vote from the attending directors, with stricter requirements for related party transactions and guarantees [39][40]. Group 5: Responsibilities of the Chairman - The chairman presides over shareholders' meetings and board meetings, ensuring the execution of board resolutions [28]. - The chairman has the authority to make urgent decisions in emergencies, subject to later reporting to the board [28][29]. Group 6: Documentation and Record-Keeping - Meeting records must accurately reflect the time, place, attendees, and decisions made, with a retention period of at least ten years [22][23]. - The board secretary is responsible for maintaining meeting documentation and ensuring confidentiality [23].

Core Viewpoint - The document outlines the governance structure and operational guidelines for the Board Secretary of Sinovac Biotech Ltd, emphasizing the importance of compliance with legal and regulatory frameworks [1][2][3]. Group 1: General Provisions - The document establishes the purpose of the guidelines, which is to regulate the behavior of the Board Secretary and enhance corporate governance [1]. - It defines the Board Secretary as a senior management position responsible for legal obligations and duties as per laws and company regulations [2]. - The Board Secretary acts as the designated liaison between the company and regulatory bodies, handling information disclosure and corporate governance matters [2][3]. Group 2: Qualifications and Conditions - The qualifications for the Board Secretary include a minimum of a college degree and at least three years of relevant experience in secretarial, management, or equity affairs [3]. - Candidates must possess knowledge in finance, law, and corporate management, and must adhere to ethical standards [3]. - Individuals with certain disqualifying conditions, such as recent administrative penalties from regulatory bodies, are prohibited from serving as Board Secretary [3]. Group 3: Appointment and Replacement - The Board Secretary is appointed or dismissed by the company's Board of Directors, and a securities affairs representative must be appointed to assist [4][5]. - The company must publicly announce the appointment of the Board Secretary and securities affairs representative, providing necessary documentation [4]. - The company is required to have valid reasons for dismissing the Board Secretary and must report the dismissal to the regulatory authority [5]. Group 4: Responsibilities and Duties - The Board Secretary is responsible for managing information disclosure, investor relations, and equity management [6]. - Duties include organizing board meetings, maintaining confidentiality of sensitive information, and ensuring compliance with legal obligations [6]. - The Board Secretary must also facilitate training for board members regarding their rights and responsibilities in information disclosure [6]. Group 5: Miscellaneous Provisions - The document states that the guidelines will be effective upon approval by the Board of Directors and will be subject to relevant laws and regulations [7]. - The Board of Directors holds the authority to amend and interpret these guidelines as necessary [7].

科兴生物制药股份有限公司 子公司管理制度 二〇二五年七月 1 | | | 第一章 总 则 第一条 科兴生物制药股份有限公司（以下简称"公司"、"母公司"）为加 强对子公司的管理，规范公司高效、有序的内部运作机制，促进子公司健康发展，维 护公司和投资者的合法权益，根据《中华人民共和国公司法》(以下简称《公司法》)、 《上市公司治理准则》、《上海证券交易所科创板股票上市规则》(以下简称 "《上市规则》")、《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》等法律、法规和规范性文件和《科兴生物制药股份有限公司章程》(以下简称 《公司章程》)的相关规定，结合公司实际情况，特制定本制度。 第二条 本制度所称公司系指科兴生物制药股份有限公司，子公司系指公司持 有其50%以上的股份，或者持有其股份在50%以下，但能够实际控制的公司。 科兴生物制药股份有限公司的各分公司、及子公司的各分公司，参照适用本制 度。 第三条 加强对子公司的管理，旨在建立有效的控制机制，对公司的组织、资 源、资产、投资以及运作进行风险控制，提高整体运作效率和抗风险能力。 第四条 公司依据对子公司资产控制和上市公司规范运作的要求，行使对子 ...

科兴生物制药股份有限公司 独立董事工作制度 （修订稿） 二〇二五年七月 | 第一章 | 总则 2 | | --- | --- | | 第二章 | 独立董事的构成 3 | | 第三章 | 独立董事的任职条件 3 | | 第四章 | 独立董事的提名、选举和更换 4 | | 第五章 | 独立董事的职责 6 | | 第六章 | 独立董事的工作条件 9 | | 第七章 | 附则 10 | 科兴生物制药股份有限公司独立董事工作制度 第一章 总则 第一条 为进一步完善科兴生物制药股份有限公司（以下简称"公司"或"本公司"） 治理结构，促进公司规范运作，切实保护股东利益，有效规避公司决策风险，现根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司治理准则》、《上 市公司独立董事管理办法》、《上海证券交易所科创板股票上市规则》（以下简称"《科 创板上市规则》"）、《科兴生物制药股份有限公司章程》（以下简称"《公司章程》"） 及其他有关法律、法规和规范性文件制定本制度。 第二条 本制度所指独立董事是指不在公司担任除独立董事及董事会专门委员 会委员之外的其他职务，并与公司及公司主要股东、实际控制人不存在直接或者间 ...